Avanos Medical, Inc.
NYSE:AVNSMedical - Devices
+$0.06 today
- Market cap
- $1.17B
- Beta
- 1.57
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$1.50
Volume 0.43M
Average 1.49M
AVNS Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Avanos Medical, Inc.NYSE: AVNS
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin widens to 6.7%
Operating margin was 6.7% in Q1 FY2026, up 2.3 pp from a year earlier. On a trailing-twelve-month basis it was -7.9%, down 15.6 pp year over year. Over 3 fiscal years it narrowed by 14.9 pp.
Context
- Operating margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 1 analysts of -11.6% for the fiscal year ending Dec 2026, down from -8.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 6.7%+56.1 pp QoQ
- Last fiscal yearDec 2025
- -8.8%-14.6 pp YoY
- LTMMar 2026
- -7.9%-15.6 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +2.3 pp | -15.7 pp | -18.1 pp |
| 1 year | -14.6 pp | -2.8 pp | +11.8 pp |
| 3 years | -14.9 pp | — | — |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -8.8%
- Year-over-year change
- -14.6pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -8.8% | -14.6pp |
| FY2024 | 2024-12-31 | 5.8% | -3.8pp |
| FY2023 | 2023-12-31 | 9.7% | +3.5pp |
| FY2022 | 2022-12-31 | 6.1% | -5.5pp |
| FY2021 | 2021-12-31 | 11.7% | — |
Operating Margin vs competitors
How AVNS compares with its peers on the latest reported figures
- AVNS's LTM Mar 2026 operating margin of -7.9% is the 3rd highest of the 11 companies compared; the peer median is -66.8%.
- Its year-over-year change of -15.6 pp is the 10th highest of 11, against a peer median of -0.2 pp.
- Over three fiscal years its change of -14.9 pp compares with a peer median of +11.7 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 10.6% | +13.2 pp | +43.0 pp | |
| LTM Apr 2026 | -3.7% | -10.1 pp | -13.6 pp | |
| LTM Mar 2026 | -7.9% | -15.6 pp | -14.9 pp | |
| LTM Mar 2026 | -21.5% | -8.9 pp | -18.9 pp | |
| LTM Mar 2026 | -39.8% | -44.5 pp | -86.1 pp | |
| LTM Mar 2026 | -65.2% | +2.1 pp | +14.1 pp | |
CBLLCeriBell, Inc. | LTM Mar 2026 | -68.3% | -4.3 pp | +73.4 pp |
| LTM Mar 2026 | -91.0% | -2.5 pp | +9.3 pp | |
| LTM Mar 2026 | -101.7% | +437.7 pp | -109.0 pp | |
| LTM Mar 2026 | -203.5% | +883822.6 pp | +3329.3 pp | |
| LTM Mar 2026 | -381.8% | +583.8 pp | +465.3 pp | |
| Peer median (excluding AVNS) | -66.8% | -0.2 pp | +11.7 pp | |
Competitors are the stored peer set for AVNS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 744.6M | 684.1M | 673.3M | 687.8M | 701.2M |
| Cost of Revenue | 364.7M | 289.9M | 293.6M | 306.5M | 352.2M |
| Gross Profit | 379.9M | 394.2M | 379.7M | 381.3M | 349M |
| Gross Margin | 51.0% | 57.6% | 56.4% | 55.4% | 49.8% |
| Research & Development | 32.3M | 30.6M | 27.2M | 26.2M | 23.1M |
| Selling, General & Admin | 260.8M | 323.1M | 287.5M | 315.1M | 218.3M |
| Operating Expenses | 293.1M | 352.3M | 314.7M | 341.3M | 410.6M |
| Depreciation & Amortization | 38.3M | 41.1M | 43.5M | 45.5M | 29M |
| EBITDA | 48.9M | 77.8M | 50.6M | (345.6M) | (33.2M) |
| EBITDA Margin | 6.6% | 11.4% | 7.5% | -50.2% | -4.7% |
| Operating Income | 86.8M | 41.9M | 65M | 40M | (61.6M) |
| Operating Margin | 11.7% | 6.1% | 9.7% | 5.8% | -8.8% |
| Interest Income | 200K | 1.2M | 2.9M | 5.1M | 3.2M |
| Interest Expense | 3.3M | 10M | 15M | 12.2M | 4M |
| Other Income / Expenses | (79.5M) | (15.2M) | (72.9M) | (443.3M) | (4.6M) |
| Income Before Tax | 7.3M | 26.7M | (7.9M) | (403.3M) | (66.2M) |
| Pre-Tax Margin | 1.0% | 3.9% | -1.2% | -58.6% | -9.4% |
| Income Tax Expense | 1M | 5.2M | 2M | (17M) | 1.7M |
| Net Income | 6.3M | 50.5M | (61.8M) | (392.1M) | (67.9M) |
| Net Margin | 0.8% | 7.4% | -9.2% | -57.0% | -9.7% |
| EPS (Basic) | 0.13 | 1.08 | (1.33) | (8.53) | (1.46) |
| EPS (Diluted) | 0.13 | 1.07 | (1.33) | (8.53) | (1.46) |
| Weighted Avg Shares | 48.1M | 46.9M | 46.6M | 46M | 46.4M |
| Weighted Avg Shares (Diluted) | 48.6M | 47.3M | 46.6M | 46M | 46.4M |
Avanos Medical, Inc.
NYSE:AVNS
Intrinsic Alpha fair value
Locked
Current Price
$24.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.